SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-268923
Filing Date
2023-11-02
Accepted
2023-11-02 08:49:00
Documents
15
Period of Report
2023-10-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d684425d8k.htm   iXBRL 8-K 43673
2 EX-10.1 d684425dex101.htm EX-10.1 17038
3 EX-99.1 d684425dex991.htm EX-99.1 18283
7 GRAPHIC g684425g1102053644145.jpg GRAPHIC 2017
  Complete submission text file 0001193125-23-268923.txt   225670

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA acer-20231031.xsd EX-101.SCH 2847
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE acer-20231031_lab.xml EX-101.LAB 18757
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acer-20231031_pre.xml EX-101.PRE 11708
9 EXTRACTED XBRL INSTANCE DOCUMENT d684425d8k_htm.xml XML 3484
Mailing Address ONE GATEWAY CENTER (300 WASHINGTON ST.) SUITE 356 NEWTON MA 02458
Business Address ONE GATEWAY CENTER (300 WASHINGTON ST.) SUITE 356 NEWTON MA 02458 (844) 902-6100
Acer Therapeutics Inc. (Filer) CIK: 0001069308 (see all company filings)

IRS No.: 320426967 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33004 | Film No.: 231370284
SIC: 2834 Pharmaceutical Preparations